InxMed Reveals Groundbreaking Data on Ifebemtinib and KRAS Inhibitor for Cancer Treatments InxMed Co., Ltd has unveiled promising Phase Ib/II trial results for Ifebemtinib combined with a KRAS G12C inhibitor, showcasing notable efficacy in treating various solid tumors.

InxMed Reveals Groundbreaking Data on Ifebemtinib and KRAS Inhibitor for Cancer Treatments #China #Nanjing #Cancer_Treatment #KRAS_G12C #Ifebemtinib